BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, February 1, 2026
Home » Authors » John Fox

John Fox

Articles

ARTICLES

New high-performance Alzheimer's disease biomarkers developed

Feb. 14, 2018
By John Fox
The first high-performance plasma biomarkers for Alzheimer's disease (AD) have been validated in an international collaborative study, which was reported in the Jan. 31, 2018, edition of Nature.
Read More

New high-performance AD biomarkers developed

Feb. 9, 2018
By John Fox

New high-performance Alzheimer's disease biomarkers developed

Feb. 9, 2018
By John Fox
The first high-performance plasma biomarkers for Alzheimer's disease (AD) have been validated in an international collaborative study, which was reported in the Jan. 31, 2018, edition of Nature.
Read More

Structural findings enable multi-GPCR targeting

Feb. 7, 2018
By John Fox
HONG KONG – The elucidation of the detailed three-dimensional (3-D) atomic structure of a key drug receptor will facilitate the design of new polypharmacology drugs capable of acting on multiple targets, opening up new ways to develop drugs for the treatment of complex diseases.
Read More

Structural findings enable multi-GPCR targeting

Feb. 2, 2018
By John Fox

Structural findings enable multi-GPCR targeting

Feb. 2, 2018
By John Fox
The elucidation of the detailed three-dimensional (3-D) atomic structure of a key drug receptor will facilitate the design of new polypharmacology drugs capable of acting on multiple targets, opening up new ways to develop drugs for the treatment of complex diseases.
Read More

New long-acting approach to malaria prophylaxis developed

Jan. 31, 2018
By John Fox
In a new study, researchers at the U.K.'s University of Liverpool and Johns Hopkins University School of Medicine in Baltimore have jointly developed a new long-acting nanomedicine-based delivery system for preventing malaria.
Read More

New genomics system enables effective new vaccines

Jan. 31, 2018
By John Fox
A new genomics system developed to identify interferon-sensitive mutations was used to generate an attenuated hyper-interferon (IFN)-susceptible influenza virus vaccine candidate, which not only elicited robust immune responses but could also be used to produce vaccines against other pathogens, Chinese and U.S. researchers reported in the Jan. 19, 2018, edition of Science.
Read More

New long-acting approach to malaria prophylaxis developed

Jan. 30, 2018
By John Fox

New long-acting approach to malaria prophylaxis developed

Jan. 30, 2018
By John Fox
In a new study, researchers at the U.K.'s University of Liverpool and Johns Hopkins University School of Medicine in Baltimore have jointly developed a new long-acting nanomedicine-based delivery system for preventing malaria.
Read More
View All Articles by John Fox

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing